Department of Pharmacy Sciences, Creighton University, 2500 California Plaza, Omaha, Nebraska68178, United States.
Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado80523, United States.
J Med Chem. 2023 Jan 12;66(1):170-187. doi: 10.1021/acs.jmedchem.2c00352. Epub 2022 Dec 23.
Tuberculosis (TB), caused by (), is one of the leading causes of death in developing countries. Non-tuberculous mycobacteria (NTM) infections are rising and prey upon patients with structural lung diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis. All mycobacterial infections require lengthy treatment regimens with undesirable side effects. Therefore, new antimycobacterial compounds with novel mechanisms of action are urgently needed. Published indole-2-carboxamides (IC) with suggested inhibition of the essential transporter MmpL3 showed good potency against whole-cell , yet had poor aqueous solubility. This project focused on retaining the required MmpL3 inhibitory pharmacophore and increasing the molecular heteroatom percentage by reducing lipophilic atoms. We evaluated pyrrole, mandelic acid, imidazole, and acetamide functional groups coupled to lipophilic head groups, where lead acetamide-based compounds maintained high potency against mycobacterial pathogens, had improved ADME profiles over their indole-2-carboxamide analogs, were non-cytotoxic, and were determined to be MmpL3 inhibitors.
结核病(TB)是由 ()引起的,是发展中国家主要的死亡原因之一。非结核分枝杆菌(NTM)感染正在上升,并侵害患有结构性肺病(如慢性阻塞性肺疾病(COPD)和囊性纤维化)的患者。所有分枝杆菌感染都需要长期的治疗方案,且具有不良的副作用。因此,迫切需要具有新作用机制的新型抗分枝杆菌化合物。已发表的吲哚-2-甲酰胺(IC)具有抑制必需转运蛋白 MmpL3 的作用,对全细胞 ()显示出良好的活性,但水溶性差。本项目专注于保留所需的 MmpL3 抑制药效团,并通过减少亲脂原子来增加分子杂原子百分比。我们评估了与亲脂性头部基团偶联的吡咯、扁桃酸、咪唑和乙酰胺官能团,其中基于乙酰胺的先导化合物对分枝杆菌病原体保持高活性,与吲哚-2-甲酰胺类似物相比,改善了 ADME 特性,无细胞毒性,并被确定为 MmpL3 抑制剂。